Pulse Biosciences (PLSE) Stock Price, News & Analysis

Company Overview

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.

Key Stats

• Today's Range: $15.31 to $15.76
• 50-Day Range: $14.71 to $17.31
• 52-Week Range: $13.77 to $25.00
• Volume: 91,586 shs
• Average Volume: 172,087 shs
• Market Capitalization: $1.05 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $22.00
• Consensus Rating: Buy

Pulse Biosciences Stock Analysis - MarketRank™

Pulse Biosciences scored higher than 80% of companies evaluated by MarketBeat, and ranked 211th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Pulse Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Pulse Biosciences has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Pulse Biosciences is -14.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Pulse Biosciences is -14.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Pulse Biosciences has a P/B Ratio of 10.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

19.44% of the float of Pulse Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Pulse Biosciences has a short interest ratio ("days to cover") of 14.7, which indicates bearish sentiment.

Change versus previous month

Short interest in Pulse Biosciences has recently increased by 0.41%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Pulse Biosciences does not currently pay a dividend.

Dividend Growth

Pulse Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -0.60

Percentage of Shares Shorted

19.44% of the float of Pulse Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Pulse Biosciences has a short interest ratio ("days to cover") of 14.7, which indicates bearish sentiment.

Change versus previous month

Short interest in Pulse Biosciences has recently increased by 0.41%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: N/A

News Sentiment

Pulse Biosciences has a news sentiment score of 1.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Pulse Biosciences this week, compared to 2 articles on an average week.

Search Interest

1 people have searched for PLSE on MarketBeat in the last 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Pulse Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $246,000.00 in company stock.

Percentage Held by Insiders

71.50% of the stock of Pulse Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

76.95% of the stock of Pulse Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PLSE Stock Analysis - Frequently Asked Questions

How have PLSE shares performed this year?

Pulse Biosciences' stock was trading at $17.41 at the beginning of the year. Since then, PLSE shares have decreased by 10.7% and is now trading at $15.54.

How were Pulse Biosciences' earnings last quarter?

Pulse Biosciences, Inc (NASDAQ:PLSE) released its quarterly earnings data on Tuesday, August, 12th. The company reported ($0.28) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by $0.02.
Read the conference call transcript.

When did Pulse Biosciences IPO?

Pulse Biosciences (PLSE) raised $20 million in an initial public offering on Wednesday, May 18th 2016. The company issued 5,000,000 shares at $4.00 per share. MDB Capital Group and Feltl and Company acted as the underwriters for the IPO.

Who are Pulse Biosciences' major shareholders?

Pulse Biosciences' top institutional shareholders include Bank of America Corp DE (1.16%), Geode Capital Management LLC (0.74%), Griffin Asset Management Inc. (0.34%) and Westside Investment Management Inc. (0.10%). Insiders that own company stock include Robert W Duggan, Darrin Uecker, Mitchell E Levinson, Mitchell E Levinson, Burke Thomas Barrett and Kevin Patrick Danahy.
View institutional ownership trends.

How do I buy shares of Pulse Biosciences?

Shares of PLSE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Pulse Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Pulse Biosciences investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), Novo Nordisk A/S (NVO) and Jabil (JBL).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 8/29/2025
• Next Earnings (Estimated): 10/29/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:PLSE
• CIK: 1625101
• Web: www.pulsebiosciences.com
• Phone: (510) 906-4600
• Fax: N/A
• Employees: 140
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Pulse Biosciences: $22.00
• High Price Target: $22.00
• Low Price Target: $22.00
• Potential Upside/Downside: +41.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.05)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$53.58 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -63.19%
• Return on Assets: -54.98%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.05
• Quick Ratio: 12.04

Sales & Book Value

• Annual Sales: $700 thousand
• Price / Sales: 1,492.65
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.55 per share
• Price / Book: 10.02

Miscellaneous

• Outstanding Shares: 67,280,000
• Free Float: 19,174,000
• Market Cap: $1.04 billion
• Optionable: Optionable
• Beta: 1.60